Excellent Long-Term Results in De Novo Renal Transplant Recipients Treated With Proliferation Signal Inhibitors and Reduced Calcineurin Inhibitors Exposure
Authors:
- M. CarmelliniMCM. Carmellini
- A. ColliniACA. Collini
- G. RuggieriGRG. Ruggieri
- G. GarosiGGG. Garosi
- M. BerniniMBM. Bernini
- 1 July 2008
- journal article
- Published by Elsevier in Transplantation Proceedings
- Vol. 40 (6) , 1858-1861
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Kidney Transplantation From Donors Aged 65 Years or More as Single or Dual GraftsTransplantation Proceedings, 2005
- Therapeutic drug monitoring for everolimus in kidney transplantation using 12‐month exposure, efficacy, and safety dataClinical Transplantation, 2005
- Benefit-Risk Assessment of Sirolimus in Renal TransplantationDrug Safety, 2005
- Everolimus and Reduced-Exposure Cyclosporine in de novo Renal-Transplant Recipients: A Three-Year Phase II, Randomized, Multicenter, Open-Label StudyTransplantation, 2004
- Everolimus with Optimized Cyclosporine Dosing in Renal Transplant Recipients: 6-Month Safety and Efficacy Results of Two Randomized StudiesAmerican Journal of Transplantation, 2004
- The Natural History of Chronic Allograft NephropathyNew England Journal of Medicine, 2003
- Post-transplant renal function in the first year predicts long-term kidney transplant survivalKidney International, 2002
- The Banff 97 working classification of renal allograft pathologyKidney International, 1999